BioPharmSignal logoBioPharmSignal

Biotech News

GH Research Welcomes White House Executive Order to Accelerate Medical Treatments for Serious Mental Illness

GH Research (GHRS)GH ResearchCompany update

DUBLIN, April 20, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today issued a statement welcoming the White House Executive Order, signed

Open original release

Related news

GHRSGH Research2026-03-25 15:11 EST

GH Research Announces Publication of Phase 2b Results for Mebufotenin (GH001) in JAMA Psychiatry and Reports New Finding of Severity-Independent Efficacy in TRD

GHRSGH Research2026-05-14 11:00 EST

GH Research Reports First Quarter 2026 Financial Results and Provides Business Update

PTIXProtagenic Therapeutics2026-04-23 08:15 EST

Protagenic Therapeutics Appoints Industry Veteran Bill Nichols Jr. as President to Accelerate Advancement of First-in-Class TCAP Pathway Therapy PT00114

TNXPTonix Pharmaceuticals2026-05-26 11:00 EST

Tonix Pharmaceuticals Presented Retrospective U.S. Real-World Claims Analysis Characterizing Patients with Fibromyalgia at The Professional Society for Health Economics and Outcomes Research (ISPOR) 2026 Annual Meeting

ALKSAlkermes plc2026-05-21 11:00 EST

Alkermes Showcases Data From Psychiatry Portfolio and Sleep Research into Real World Patient Experience at Spring 2026 Scientific Conferences

ABOSAcumen Pharmaceuticals2026-03-17 12:00 EST

Acumen Pharmaceuticals Presents Studies on Enhanced Brain Delivery™, Biomarker Research, and Novel Antibodies at Advances in Alzheimer's Treatment at International Conference on Alzheimer’s and Parkinson’s Diseases 2026

IKTInhibikase Therapeutics2026-07-23 12:00 EST

Inhibikase Therapeutics Announces FDA Orphan Drug Designation Granted to IKT-001 for the Treatment of PAH

AXSMAxsome2026-07-15 11:00 EST

Axsome Therapeutics Announces FDA Acceptance of New Drug Application for AXS-12 for the Treatment of Cataplexy in Narcolepsy

TSHATaysha Gene Therapies2026-06-22 12:00 EST

Taysha Gene Therapies Announces Completion of Dosing in REVEAL Pivotal Trial and Reports Longer-Term Clinical Data from Part A of REVEAL Phase 1/2 Trials Evaluating TSHA-102 for Rett Syndrome

KTTAPasithea Therapeutics2026-06-16 11:00 EST

Pasithea Therapeutics Announces Amendments to Clinical Study Protocol for Phase 1/1B NF1 Clinical Trial

View all latest news

GH Research

GH Research is a neuroscience company developing psychedelic-inspired therapies for treatment-resistant depression and related disorders. Its work centers on novel CNS mechanisms and differentiated psychiatric care.

Recent company news

GHRSGH Research2026-06-04 11:00 EST

GH Research Announces Publication of Phase 2a Postpartum Depression Results

GHRSGH Research2026-05-14 11:00 EST

GH Research Reports First Quarter 2026 Financial Results and Provides Business Update

GHRSGH Research2026-04-29 12:00 EST

GH Research Announces Pricing of $117.5 Million Underwritten Offering

GHRSGH Research2026-04-20 13:00 EST

GH Research Welcomes White House Executive Order to Accelerate Medical Treatments for Serious Mental Illness

GHRSGH Research2026-03-25 15:11 EST

GH Research Announces Publication of Phase 2b Results for Mebufotenin (GH001) in JAMA Psychiatry and Reports New Finding of Severity-Independent Efficacy in TRD

Stock data

Close
27.75 USD
Market cap
1.71B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States